FDA Breakthrough Therapy granted to bladder cancer treatment
FDA Breakthrough Therapy Designation has been granted to PADCEV™ in…
FDA Breakthrough Therapy Designation has been granted to PADCEV™ in combination with pembrolizumab in first-line advanced bladder cancer.